Additive blockade of β2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate Source: Eur Respir J 2004; 24: 333 Year: 2004
Long-term effect of salmeterol and fluticasone propionate on β2 -integrin mediated adhesion of neutrophils: role of annexin-1 in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004
Timecourse of action of two inhaled corticosteroids, fluticasone propionate and budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002
The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Synergistic effect of fluticasone propionate and salmeterol on T-lymphocytes in inhibiting proliferation in vitro Source: Annual Congress 2009 - Inflammatory cells and cytokines Year: 2009
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Effect of fluticasone propionate (FP)/salmeterol 100/50mcg or FP 250mcg on small airway function Source: Eur Respir J 2003; 22: Suppl. 45, 260s Year: 2003
Inhibition of allergen-iduced late asthmatic reaction by montelukast versus fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 349s Year: 2003
Anti-inflammatory effect of beclomethasone dipropionate and formoterol on TNF-α-induced human endothelial cell activation Source: Annual Congress 2011 - Lung cell biology Year: 2011
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slicesSource: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Inhibitory activities of fluticasone propionate and salmeterol on airway epithelial cell functions (FLIC24): adhesion molecule expression and cytokine release Source: Eur Respir J 2001; 18: Suppl. 33, 246s Year: 2001
The potency ratio fluticasone propionate / budesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003